Drug for Multiple Myeloma Demonstrated to Significantly Extend Disease-Free Survival
Monday, December 21, 2009 - 15:56
in Health & Medicine
(PhysOrg.com) -- Initial results from a large, randomized clinical trial for patients with multiple myeloma, a cancer of the blood and bone marrow, showed that patients who received the oral drug lenalidomide (Revlimid, also known as CC-5013) following a blood stem cell transplant had their cancer kept in check longer than patients who received a placebo.